 |
Top 10 Parkinson's disease startups in USA
Updated: May 10, 2024 |
1
Funding: $1.1B
Neurodegenerative diseases are one of the largest medical challenges of our time. Denali Therapeutics is dedicated to defeating neurodegenerative diseases through rigorous therapeutic discovery and development.
Neurodegenerative diseases are one of the largest medical challenges of our time. Denali Therapeutics is dedicated to defeating neurodegenerative diseases through rigorous therapeutic discovery and development.
2
Funding: $374M
Voyager Therapeutics is a clinical stage gene therapy company developing life-changing treatments for severe diseases of the central nervous system (CNS). Gene therapy has the potential to transform the treatment of CNS and other diseases by providing a one-time therapy that dramatically improves patients' lives.
Voyager Therapeutics is a clinical stage gene therapy company developing life-changing treatments for severe diseases of the central nervous system (CNS). Gene therapy has the potential to transform the treatment of CNS and other diseases by providing a one-time therapy that dramatically improves patients' lives.
3
Funding: $264M
Aspen Neuroscience is a private biotechnology company that uses innovative genomic approaches combined with stem cell biology.
Aspen Neuroscience is a private biotechnology company that uses innovative genomic approaches combined with stem cell biology.
4
Funding: $260M
Neurocrine Biosciences engages in the discovery and development of drugs for the treatment of neurological and endocrine-related diseases.
Neurocrine Biosciences engages in the discovery and development of drugs for the treatment of neurological and endocrine-related diseases.
5
Funding: $213.5M
Neuron23 is a developer of drugs intended to treat Parkinson's disease and Alzheimer's disease.
Neuron23 is a developer of drugs intended to treat Parkinson's disease and Alzheimer's disease.
6
Funding: $181.2M
Skyhawk's is developing small molecule therapeutics that correct RNA expression.Their proprietary technology enables the rational design of small molecules that target the RNA splicing process.They are now developing drug candidates for cancer, neurological disease, and rare disease.
Skyhawk's is developing small molecule therapeutics that correct RNA expression.Their proprietary technology enables the rational design of small molecules that target the RNA splicing process.They are now developing drug candidates for cancer, neurological disease, and rare disease.
7
Funding: $148.3M
Cala Health is a medical technology company pioneering a new class of electrical medicine called neuroperipheral therapy. Neuroperipheral therapy has the potential to address chronic disease by externally stimulating peripheral nerves with body-worn electronics. Cala Health is bringing together experts in neuroscience, consumer electronics, and medical devices to develop accessible therapies that treat chronic disease non-invasively.
Cala Health is a medical technology company pioneering a new class of electrical medicine called neuroperipheral therapy. Neuroperipheral therapy has the potential to address chronic disease by externally stimulating peripheral nerves with body-worn electronics. Cala Health is bringing together experts in neuroscience, consumer electronics, and medical devices to develop accessible therapies that treat chronic disease non-invasively.
8
Funding: $137.4M
Yumanity Therapeutics is transforming drug discovery for neurodegenerative diseases caused by protein misfolding. Yumanity is working to identify and develop new, disease-modifying therapies that address several illnesses with critical unmet medical needs. The initial focus of the company is neurodegenerative diseases, including Alzheimer’s disease, Parkinson’s disease and amyotrophic lateral sclerosis (ALS).
Yumanity Therapeutics is transforming drug discovery for neurodegenerative diseases caused by protein misfolding. Yumanity is working to identify and develop new, disease-modifying therapies that address several illnesses with critical unmet medical needs. The initial focus of the company is neurodegenerative diseases, including Alzheimer’s disease, Parkinson’s disease and amyotrophic lateral sclerosis (ALS).
9
Funding: $134.1M
We use genomic data to find better drugs, faster. We find new cures for brain diseases 1000X more cheaply and quickly using our proven network algorithms.
We use genomic data to find better drugs, faster. We find new cures for brain diseases 1000X more cheaply and quickly using our proven network algorithms.
10
Funding: $129M
Prevail Therapeutics is a biotechnology company focused on developing novel gene therapies for patients with Parkinson’s disease and other neurodegenerative diseases.
Prevail Therapeutics is a biotechnology company focused on developing novel gene therapies for patients with Parkinson’s disease and other neurodegenerative diseases.
Ad
Advertise your startup
11
Funding: $115.9M
Axial Biotherapeutics is a biopharmaceutical company harnessing the link between the human gut microbiome and Central Nervous System to develop a new class of therapeutics to improve the quality of life for people with CNS diseases and disorders
Axial Biotherapeutics is a biopharmaceutical company harnessing the link between the human gut microbiome and Central Nervous System to develop a new class of therapeutics to improve the quality of life for people with CNS diseases and disorders
12
Funding: $92M
vTv Therapeutics, a pharmaceutical company, focuses on the discovery and development of human therapeutics to fill unmet medical needs. Its mission is to utilize its innovative technology to rapidly translate the functional modulation of human proteins into safe and effective medicines.
vTv Therapeutics, a pharmaceutical company, focuses on the discovery and development of human therapeutics to fill unmet medical needs. Its mission is to utilize its innovative technology to rapidly translate the functional modulation of human proteins into safe and effective medicines.
13
Funding: $36M
Neuraly is a Johns Hopkins School of Medicine spinoff biotech company and aims to introduce the first, disease-modifying agent for neurodegenerative disorders and aging.
Neuraly is a Johns Hopkins School of Medicine spinoff biotech company and aims to introduce the first, disease-modifying agent for neurodegenerative disorders and aging.
14
Funding: $29M
Appello Pharmaceuticals is focused on advancing novel positive allosteric modulators of mGlu4 for the treatment of Parkinson’s disease.
Appello Pharmaceuticals is focused on advancing novel positive allosteric modulators of mGlu4 for the treatment of Parkinson’s disease.
15
Funding: $12.5M
OccamzRazor uses machine learning to find and develop curative treatments for Parkinson’s.
OccamzRazor uses machine learning to find and develop curative treatments for Parkinson’s.
16
Funding: $4.3M
De Oro Devices is a device that re-establishing the connection between the brain and the body.
De Oro Devices is a device that re-establishing the connection between the brain and the body.
17
Funding: $2.9M
Liftware is a stabilizing handle and a selection of attachments that include a soup spoon, everyday spoon, and fork. Liftware is designed to help people with hand tremor eat more easily.
Liftware is a stabilizing handle and a selection of attachments that include a soup spoon, everyday spoon, and fork. Liftware is designed to help people with hand tremor eat more easily.
18
Funding: $500K
MentiNova’s primary strategy is to use L-DOPA, the drug that is currently clinically approved for another indication and repurpose it for the treatment of L-Dopa Induced Dyskinesia in patients with Parkinson’s disease.
MentiNova’s primary strategy is to use L-DOPA, the drug that is currently clinically approved for another indication and repurpose it for the treatment of L-Dopa Induced Dyskinesia in patients with Parkinson’s disease.
19
Funding: $375K
AbiliLife is a company dedicated to designing and developing products to improve the quality of life for patients with Parkinson’s and other neurodegenerative diseases.
AbiliLife is a company dedicated to designing and developing products to improve the quality of life for patients with Parkinson’s and other neurodegenerative diseases.
20
Funding: $375K
Melior Pharmaceuticals is a clinical stage pharmaceutical company developing treatment for metabolic disease and skin disorders.
Melior Pharmaceuticals is a clinical stage pharmaceutical company developing treatment for metabolic disease and skin disorders.
21
Funding: $250K
Convalesce is a therapeutic company enabling stem cell-based therapy for neurodegenerative conditions like Parkinson's, harnessing state-of-art biomaterials.
Convalesce is a therapeutic company enabling stem cell-based therapy for neurodegenerative conditions like Parkinson's, harnessing state-of-art biomaterials.
22
Cortera Neurotechnologies designs medical devices aimed at revolutionizing the treatment of intractable neurological conditions.
23
VistaraBio is applying their proteostasis technologies for target identification in Parkinson's and other neurodegenerative diseases.